Dechra
Dechra Pharmaceuticals PLC, commonly known as Dechra, is a leading global veterinary pharmaceutical company headquartered in the United Kingdom. Founded in 1997, Dechra has established a strong presence in Europe, North America, and Australia, focusing on the development and marketing of high-quality products for companion animals and livestock. Specialising in veterinary medicines, Dechra offers a diverse range of core products, including anaesthetics, dermatology treatments, and nutritional supplements. What sets Dechra apart is its commitment to innovation and quality, ensuring that its products meet the highest standards of safety and efficacy. With a robust market position, Dechra has achieved significant milestones, including numerous product launches and strategic acquisitions, solidifying its reputation as a trusted partner in animal health. The company continues to lead the way in veterinary pharmaceuticals, dedicated to improving the health and well-being of animals worldwide.
DitchCarbon Score
How does Dechra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dechra's score of 54 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dechra's reported carbon emissions
In 2022, Dechra Pharmaceuticals PLC reported total carbon emissions of approximately 14,375,000 kg CO2e globally, with specific emissions of about 6,709,000 kg CO2e from Scope 1, 4,896,000 kg CO2e from Scope 2, and 2,770,000 kg CO2e from Scope 3. In the UK, their emissions were about 1,241,901 kg CO2e, comprising 489,757 kg CO2e from Scope 1, 607,104 kg CO2e from Scope 2, and 144,040 kg CO2e from Scope 3. Dechra has set ambitious climate commitments, aiming for a 90% reduction in absolute Scope 1 and 2 emissions by 2050, based on a 2021 baseline. They also target a 42% reduction in these emissions by 2030. For Scope 3 emissions, the company aims for a 97% reduction per GBP value added by 2050 and a 51.6% reduction by 2030. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. Overall, Dechra's commitment to achieving net-zero greenhouse gas emissions across its value chain by 2050 reflects a strong dedication to sustainability and climate action within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 6,747,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 4,969,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 2,347,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dechra is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
